RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE)
Lung cancer is one of the most common malignant tumors. As over 70 % of patients at diagnosis have locally advanced or generalized process, the majority of patients receive drug treatment only. We evaluated effectiveness and toxicity of pemetrexed (Alimta) in 24 patients with locally advanced and me...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-04-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/305 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849253087872548864 |
|---|---|
| author | L. Yu. Vladimirova A. E. Storozhakova S. N. Kabanov E. A. Kalabanova |
| author_facet | L. Yu. Vladimirova A. E. Storozhakova S. N. Kabanov E. A. Kalabanova |
| author_sort | L. Yu. Vladimirova |
| collection | DOAJ |
| description | Lung cancer is one of the most common malignant tumors. As over 70 % of patients at diagnosis have locally advanced or generalized process, the majority of patients receive drug treatment only. We evaluated effectiveness and toxicity of pemetrexed (Alimta) in 24 patients with locally advanced and metastatic non-squamous cell non-small-cell lung carcinoma with the known EGFR mutation status. Pemetrexed 500 mg/m2 was administered as monotherapy (8 patients) or in combination with platinum-based drugs (15 patients). Three (12.5 %) patients showed complete regression, 7 (29.2 %) – partial regression, 10 (41.7 %) – stabilization, 4 (16.6 %) – progression. The median survival was 14.8 months. Non-hematological complications were registered, usually concerning the digestive system. Hematological complications included first-degree leukopenia – 27 (21.3 %), second- and third-degree thrombocytopenia – 1 case of each (0.8%). The complications did not require administration of drugs or were corrected medicamentally. We observed a high effectiveness of pemetrexed in patients with non-squamous NSCLC, as well as a low rate of complications and controlled toxicity. |
| format | Article |
| id | doaj-art-3601c8110b5c4e8f9ede7bd55311c63f |
| institution | Kabale University |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2016-04-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-3601c8110b5c4e8f9ede7bd55311c63f2025-08-20T03:56:27ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682016-04-01151263010.21294/1814-4861-2016-15-1-26-30305RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE)L. Yu. Vladimirova0A. E. Storozhakova1S. N. Kabanov2E. A. Kalabanova3Rostov Research Institute of OncologyRostov Research Institute of OncologyRostov Research Institute of OncologyRostov Research Institute of OncologyLung cancer is one of the most common malignant tumors. As over 70 % of patients at diagnosis have locally advanced or generalized process, the majority of patients receive drug treatment only. We evaluated effectiveness and toxicity of pemetrexed (Alimta) in 24 patients with locally advanced and metastatic non-squamous cell non-small-cell lung carcinoma with the known EGFR mutation status. Pemetrexed 500 mg/m2 was administered as monotherapy (8 patients) or in combination with platinum-based drugs (15 patients). Three (12.5 %) patients showed complete regression, 7 (29.2 %) – partial regression, 10 (41.7 %) – stabilization, 4 (16.6 %) – progression. The median survival was 14.8 months. Non-hematological complications were registered, usually concerning the digestive system. Hematological complications included first-degree leukopenia – 27 (21.3 %), second- and third-degree thrombocytopenia – 1 case of each (0.8%). The complications did not require administration of drugs or were corrected medicamentally. We observed a high effectiveness of pemetrexed in patients with non-squamous NSCLC, as well as a low rate of complications and controlled toxicity.https://www.siboncoj.ru/jour/article/view/305non-small-cell lung cancer, adenocarcinoma of the lung, egfr mutation, chemotherapy, pemetrexed |
| spellingShingle | L. Yu. Vladimirova A. E. Storozhakova S. N. Kabanov E. A. Kalabanova RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE) Сибирский онкологический журнал non-small-cell lung cancer, adenocarcinoma of the lung, egfr mutation, chemotherapy, pemetrexed |
| title | RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE) |
| title_full | RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE) |
| title_fullStr | RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE) |
| title_full_unstemmed | RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE) |
| title_short | RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE) |
| title_sort | results of treatment of patients with locally advanced and metastatic non squamous cell non small cell lung carcinoma with pemetrexed by own experience |
| topic | non-small-cell lung cancer, adenocarcinoma of the lung, egfr mutation, chemotherapy, pemetrexed |
| url | https://www.siboncoj.ru/jour/article/view/305 |
| work_keys_str_mv | AT lyuvladimirova resultsoftreatmentofpatientswithlocallyadvancedandmetastaticnonsquamouscellnonsmallcelllungcarcinomawithpemetrexedbyownexperience AT aestorozhakova resultsoftreatmentofpatientswithlocallyadvancedandmetastaticnonsquamouscellnonsmallcelllungcarcinomawithpemetrexedbyownexperience AT snkabanov resultsoftreatmentofpatientswithlocallyadvancedandmetastaticnonsquamouscellnonsmallcelllungcarcinomawithpemetrexedbyownexperience AT eakalabanova resultsoftreatmentofpatientswithlocallyadvancedandmetastaticnonsquamouscellnonsmallcelllungcarcinomawithpemetrexedbyownexperience |